Reboxetine's place in antidepressant therapy

From symptoms to social functioning: differential effects of antidepressant therapy.

Kasper S

Department of General Psychiatry,
University of Vienna, Austria.
Int Clin Psychopharmacol 1999 May; 14 Suppl 1:S27-31

ABSTRACT

Significant impairments in social functioning frequently occur simultaneously with depressive symptoms. The implications of such impairments extend beyond the depressed individual to their family, friends and society at large. Classical rating scales such as the Hamilton rating scale for depression primarily assess the core symptoms of depression. A range of rating scales are available, both self-reporting and administered by clinician; however, many have been criticized for their unspecified conceptual background and for being complex and time-consuming. While antidepressants in general appear to improve social functioning, no clear advantage for any single class of agent has been reported. Recently, a new self-report rating scale, the Social Adaptation Self-evaluation Scale, has been developed and used to compare the novel selective noradrenaline reuptake inhibitor, reboxetine, with the selective serotonin re-uptake inhibitor, fluoxetine. The noradrenergic agent, reboxetine, was shown to be significantly more effective in improving social functioning than the serotonergic agent, fluoxetine. These findings are consistent with previous observations that noradrenaline may preferentially improve vigilance, motivation, and self-perception

Tianeptine | Moclobemide | Deprenyl | Picamilon | cataract
Home | Order
www.AlzheimersTreatments.com

                    Reboxetine  research / abstracts

  1. Reboxetine role in antidepressant therapy
2. Reboxetine efficacy and tolerability
  3. Reboxetine clinical pharmacologic profile
4. Reboxetine Inhibiting noradrenaline and serotonin reuptake
5. Reboxetine and depression in the elderly
6. Reboxetine with severe major depressive disorder
7. Reboxetine clinical efficacy in major depression
8. Reboxetine tolerability and safety for major depression
9. Reboxetine comparison with fluoxetine
10. Reboxetine versus fluoxetine, impact on social functioning
11. Reboxetine  versus fluoxetine, differential effects
12. Reboxetine prevents relapse in major depression
13. Reboxetine efficacy compared with imipramine
14. Noradrenaline reuptake inhibition
15. Antidepressants noradrenergic versus serotonergic
16. Reboxetine in the treatment of bulimia
17. Reboxetine hemodynamic effects in healthy males
18. Reboxetine effects of antidepressant therapy
19. Reboxetine place in antidepressant therapy
20. Reboxetine stimulant effects in patients with narcolepsy
21. Reboxetine selective noradrenaline reuptake inhibitor (NARI)
     Reboxetine manufacturer's product insert

HOME to order